Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma
-
- MIYAMOTO Chihiro
- Department of Oral Science, Graduate School, Kanagawa Dental University Oral Health Science Research Center, Graduate School, Kanagawa Dental University
-
- MAEHATA Yojiro
- Department of Oral Science, Graduate School, Kanagawa Dental University Oral Health Science Research Center, Graduate School, Kanagawa Dental University
-
- MOTOHASHI Kazuhiko
- Department of Oral Science, Graduate School, Kanagawa Dental University
-
- OZAWA Shigeyuki
- Oral Health Science Research Center, Graduate School, Kanagawa Dental University Department of Oral Surgery, Graduate School, Kanagawa Dental University
-
- IKOMA Takeharu
- Oral Health Science Research Center, Graduate School, Kanagawa Dental University Department of Oral Surgery, Graduate School, Kanagawa Dental University
-
- HIDAKA Kouki
- Department of Periodontal Regeneration, Kanagawa Dental University
-
- WADA-TAKAHASHI Satoko
- Department of Oral Science, Graduate School, Kanagawa Dental University
-
- TAKAHASHI Shun-Suke
- Department of Oral Science, Graduate School, Kanagawa Dental University
-
- YOSHINO Fumihiko
- Department of Oral Science, Graduate School, Kanagawa Dental University
-
- YOSHIDA Ayaka
- Department of Oral Science, Graduate School, Kanagawa Dental University
-
- KUBOTA Eiro
- Oral Health Science Research Center, Graduate School, Kanagawa Dental University Department of Oral Surgery, Graduate School, Kanagawa Dental University
-
- HATA Ryu-Ichiro
- Department of Oral Science, Graduate School, Kanagawa Dental University Oral Health Science Research Center, Graduate School, Kanagawa Dental University
-
- LEE Masaichi-Chang-il
- Yokosuka-Shonan Disaster Health Emergency Research Center, Graduate School, Kanagawa Dental University
書誌事項
- タイトル別名
-
- <b>Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell car</b><b>cinoma </b>
- a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma
この論文をさがす
抄録
CXCL14/BRAK (BRAK) is a secreted chemokine with anti-tumor activity, and its expression is suppressed in tumor cells. We previously reported the anti-tumor activity of BRAK in cell lines of head and neck squamous cell carcinoma (HNSCC) and the suppression of BRAK secretion in these cells. BRAK secretion in fibrosarcoma cells is restored by Fasudil, which is a Rho-kinase (ROCK) inhibitor. In this study, we examined the anti-tumor effect of BRAK by evaluating its gene expression and protein secretion in HNSCC cell lines. We found that BRAK mediated the suppressive effect of Fasudil against HNSCC cells. Tumor development in female BALB/cAJclnu/nu mice was suppressed by Fasudil. Also secretion of BRAK protein by tumor cell lines in vitro was significantly stimulated by Fasudil treatment. Similarly, the production of BRAK protein was significantly increased by the addition of Fasudil to cultured tumor cells. Furthermore Fasudil significantly increased BRAK gene expression at the mRNA level in HNSCC cell line. Inhibition of the RhoA/ROCK pathway by siRNAs significantly stimulated BRAK gene expression. These results show that the tumor-suppressive effect of Fasudil was mediated by BRAK, suggesting that Fasudil may therefore be useful for the treatment of HNSCC.
収録刊行物
-
- Biomedical Research
-
Biomedical Research 35 (6), 381-388, 2014
バイオメディカルリサーチプレス